FDA Cardio-Renal Division Accepts Neurochem’s Fibrillex For Pilot 2 Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Selection for the continuous marketing application program could expedite review of the amyloidosis treatment, which is targeted for NDA filing in 2005. The pilot 2 program builds upon an earlier collaboration between Neurochem and FDA through which the agency provided funding for a Fibrillex Phase II/III clinical trial.
You may also be interested in...
Neurochem Submits First Unit Of Fibrillex Rolling NDA
The amyloid A amyloidosis agent is part of the Pilot 1 and Pilot 2 programs overseen by FDA's Division of Cardio-Renal Drug Products.
Neurochem Submits First Unit Of Fibrillex Rolling NDA
The amyloid A amyloidosis agent is part of the Pilot 1 and Pilot 2 programs overseen by FDA's Division of Cardio-Renal Drug Products.
FDA Extends Deadline For Continuous Marketing Application Pilot 2 Again
The agency is accepting applications for the fast-track IND pilot program until Dec. 31. Applications will only be accepted by those divisions of the drug and biologics centers that have not previously selected a Pilot 2 application.